Neuphoria Therapeutics (NEUP) Competitors $7.13 +0.11 (+1.57%) As of 01:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsOwnershipSEC FilingsTrendsBuy This Stock NEUP vs. IPA, TELO, VTVT, RNXT, IPSC, BLUE, PRLD, STTK, KLRS, and AADIShould you be buying Neuphoria Therapeutics stock or one of its competitors? The main competitors of Neuphoria Therapeutics include ImmunoPrecise Antibodies (IPA), Telomir Pharmaceuticals (TELO), vTv Therapeutics (VTVT), RenovoRx (RNXT), Century Therapeutics (IPSC), bluebird bio (BLUE), Prelude Therapeutics (PRLD), Shattuck Labs (STTK), Kalaris Therapeutics (KLRS), and Aadi Bioscience (AADI). These companies are all part of the "pharmaceutical products" industry. Neuphoria Therapeutics vs. Its Competitors ImmunoPrecise Antibodies Telomir Pharmaceuticals vTv Therapeutics RenovoRx Century Therapeutics bluebird bio Prelude Therapeutics Shattuck Labs Kalaris Therapeutics Aadi Bioscience ImmunoPrecise Antibodies (NASDAQ:IPA) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership. Which has more volatility and risk, IPA or NEUP? ImmunoPrecise Antibodies has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500. Comparatively, Neuphoria Therapeutics has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500. Which has preferable earnings & valuation, IPA or NEUP? Neuphoria Therapeutics has lower revenue, but higher earnings than ImmunoPrecise Antibodies. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunoPrecise Antibodies$18.16M3.36-$20.13M-$1.16-1.15Neuphoria Therapeutics$10K1,340.44-$15.49MN/AN/A Does the media prefer IPA or NEUP? In the previous week, ImmunoPrecise Antibodies and ImmunoPrecise Antibodies both had 1 articles in the media. ImmunoPrecise Antibodies' average media sentiment score of 0.00 equaled Neuphoria Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunoPrecise Antibodies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Neuphoria Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is IPA or NEUP more profitable? Neuphoria Therapeutics has a net margin of 0.00% compared to ImmunoPrecise Antibodies' net margin of -190.76%. Neuphoria Therapeutics' return on equity of 0.00% beat ImmunoPrecise Antibodies' return on equity.Company Net Margins Return on Equity Return on Assets ImmunoPrecise Antibodies-190.76% -88.87% -49.26% Neuphoria Therapeutics N/A N/A N/A Do insiders and institutionals believe in IPA or NEUP? 6.7% of ImmunoPrecise Antibodies shares are held by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are held by institutional investors. 6.8% of ImmunoPrecise Antibodies shares are held by company insiders. Comparatively, 0.7% of Neuphoria Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts rate IPA or NEUP? ImmunoPrecise Antibodies presently has a consensus target price of $4.00, indicating a potential upside of 199.63%. Neuphoria Therapeutics has a consensus target price of $21.00, indicating a potential upside of 194.53%. Given ImmunoPrecise Antibodies' higher probable upside, analysts plainly believe ImmunoPrecise Antibodies is more favorable than Neuphoria Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmunoPrecise Antibodies 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Neuphoria Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryNeuphoria Therapeutics beats ImmunoPrecise Antibodies on 7 of the 11 factors compared between the two stocks. Get Neuphoria Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NEUP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NEUP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NEUP vs. The Competition Export to ExcelMetricNeuphoria TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.20M$2.91B$5.54B$8.95BDividend YieldN/A2.42%5.38%4.08%P/E RatioN/A21.4227.3820.03Price / Sales1,340.44285.81422.31120.16Price / CashN/A41.9536.6357.47Price / Book0.457.518.085.67Net Income-$15.49M-$55.05M$3.16B$248.47M7 Day Performance4.85%3.16%2.12%2.90%1 Month Performance4.09%5.92%4.43%5.75%1 Year PerformanceN/A5.82%35.62%21.36% Neuphoria Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NEUPNeuphoria Therapeutics1.3717 of 5 stars$7.13+1.6%$21.00+194.5%N/A$13.20M$10K0.00N/AGap DownIPAImmunoPrecise Antibodies1.7711 of 5 stars$1.11flat$4.00+260.4%+1.0%$50.80M$18.16M-0.9680News CoverageTELOTelomir Pharmaceuticals2.6332 of 5 stars$1.53-10.0%$15.00+880.4%-70.9%$50.60MN/A-3.641High Trading VolumeVTVTvTv Therapeutics2.0576 of 5 stars$14.49-6.8%$35.50+145.0%-17.6%$49.67M$1.02M-4.819High Trading VolumeRNXTRenovoRx2.8906 of 5 stars$1.28-5.2%$7.25+466.4%+15.0%$49.37M$40K-3.206Positive NewsHigh Trading VolumeIPSCCentury Therapeutics2.6971 of 5 stars$0.52-8.6%$4.20+709.7%-74.9%$48.90M$6.59M-1.79170High Trading VolumeBLUEbluebird bio2.1147 of 5 stars$4.97flat$44.60+797.4%N/A$48.67M$103.95M-0.13520News CoveragePRLDPrelude Therapeutics3.4575 of 5 stars$0.79-8.7%$4.50+473.0%-78.6%$48.56M$7M-0.46120High Trading VolumeSTTKShattuck Labs2.8731 of 5 stars$0.85-14.6%$7.50+778.5%-76.7%$47.90M$5.72M-0.61100News CoveragePositive NewsHigh Trading VolumeKLRSKalaris TherapeuticsN/A$2.62+2.3%N/AN/A$47.88MN/A0.00110Positive NewsGap UpAADIAadi Bioscience0.6753 of 5 stars$1.93+1.6%$1.67-13.6%+40.9%$47.67M$25.07M-0.8540 Related Companies and Tools Related Companies IPA Competitors TELO Competitors VTVT Competitors RNXT Competitors IPSC Competitors BLUE Competitors PRLD Competitors STTK Competitors KLRS Competitors AADI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NEUP) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuphoria Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuphoria Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NEUP Stock Alerts